Bank of New York Mellon Corp Grows Position in STERIS plc $STE

Bank of New York Mellon Corp raised its stake in STERIS plc (NYSE:STE) by 1.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 558,038 shares of the medical equipment provider’s stock after acquiring an additional 8,839 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.57% of STERIS worth $138,081,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Mediolanum International Funds Ltd increased its stake in STERIS by 9.0% in the second quarter. Mediolanum International Funds Ltd now owns 62,327 shares of the medical equipment provider’s stock valued at $14,883,000 after purchasing an additional 5,156 shares during the last quarter. Entropy Technologies LP grew its holdings in STERIS by 282.2% in the 2nd quarter. Entropy Technologies LP now owns 9,099 shares of the medical equipment provider’s stock valued at $2,186,000 after buying an additional 6,718 shares during the period. Vanguard Group Inc. grew its holdings in STERIS by 1.7% in the 2nd quarter. Vanguard Group Inc. now owns 12,163,128 shares of the medical equipment provider’s stock valued at $2,921,827,000 after buying an additional 205,276 shares during the period. Asset Management One Co. Ltd. increased its stake in shares of STERIS by 5.4% during the 3rd quarter. Asset Management One Co. Ltd. now owns 98,487 shares of the medical equipment provider’s stock valued at $24,366,000 after acquiring an additional 5,072 shares during the last quarter. Finally, Cerity Partners LLC lifted its holdings in shares of STERIS by 28.8% during the 3rd quarter. Cerity Partners LLC now owns 96,853 shares of the medical equipment provider’s stock worth $23,966,000 after acquiring an additional 21,656 shares during the period. Institutional investors and hedge funds own 94.69% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a report on Friday, January 9th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $273.50.

STERIS Trading Up 0.4%

NYSE STE opened at $262.81 on Friday. The firm has a market capitalization of $25.79 billion, a price-to-earnings ratio of 37.76 and a beta of 1.03. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.63 and a current ratio of 2.37. STERIS plc has a one year low of $204.90 and a one year high of $269.44. The company’s 50 day moving average price is $259.30 and its 200 day moving average price is $248.75.

STERIS (NYSE:STE) last released its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.38 by $0.09. STERIS had a net margin of 12.07% and a return on equity of 14.43%. The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. During the same quarter in the prior year, the business earned $2.14 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. On average, sell-side analysts predict that STERIS plc will post 9.08 EPS for the current year.

STERIS Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Tuesday, February 17th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Tuesday, February 17th. STERIS’s payout ratio is currently 36.21%.

Insider Transactions at STERIS

In other news, VP Julia Madsen sold 5,008 shares of the company’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $262.00, for a total value of $1,312,096.00. Following the completion of the sale, the vice president owned 10,710 shares of the company’s stock, valued at $2,806,020. This represents a 31.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP John Adam Zangerle sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $265.14, for a total value of $3,977,100.00. Following the sale, the vice president owned 33,669 shares in the company, valued at approximately $8,926,998.66. The trade was a 30.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 25,044 shares of company stock valued at $6,586,218 over the last quarter. Company insiders own 1.07% of the company’s stock.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.